SCHEMBL786015

SCHEMBL786015

CN(C)c1cc(Br)ccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
EED O75530 1/20 0.39
DYRK1A Q13627 1/20 0.38
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
EGFR P00533 4/20 0.37
CYP1A2 P05177 3/20 0.34
CYP2C19 P33261 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2D6 P10635 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PROKR1 Q8TCW9 2/20 0.34
HRH4 Q9H3N8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30080735 1.00 ALDH1A1 (0.41) ALDH1A1KDM4ESMN1; SMN2GABRA1GABRG2
SCHEMBL23729975 0.79 GBA1 (0.39) ALDH1A1KDM4ESMN1; SMN2PROKR1HCRTR1
SCHEMBL25341023 0.78 HRH4 (0.35) ALDH1A1KDM4ESMN1; SMN2CYP1A2CYP3A4
SCHEMBL22306680 0.77 GBA1 (0.53) ALDH1A1KDM4ESMN1; SMN2HTTNPC1
SCHEMBL29849753 0.77 HCRTR1 (0.44) ALDH1A1KDM4ESMN1; SMN2PROKR1HCRTR1
SCHEMBL22291030 0.77 HRH3 (0.53) ALDH1A1KDM4ESMN1; SMN2EGFRCYP1A2
SCHEMBL17439216 0.77 ALDH1A1 (0.46) ALDH1A1KDM4ESMN1; SMN2DYRK1AHCRTR1
SCHEMBL20875307 0.77 SLC22A12 (0.39) ALDH1A1KDM4ESMN1; SMN2CYP1A2CYP3A4
SCHEMBL18133484 0.77 PROKR1 (0.41) ALDH1A1KDM4ESMN1; SMN2EGFRCYP2C19
SCHEMBL3475222 0.77 ALDH1A1 (0.50) ALDH1A1KDM4ESMN1; SMN2CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856736-B1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2026-05-06 EP disclosed
US-20250360141-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2025-11-27 US disclosed
US-12433897-B2 Pyridine derivatives with n-linked cyclic substituents as cGAS inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-10-07 US disclosed
WO-2025133338-A1 QUINOLONE DERIVATVES AGAINST CANCER GENOME THERAPEUTICS LTD (GB) 2025-06-26 WO disclosed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-12202816-B2 Compounds as NADPH oxidase inhibitors CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2025-01-21 US disclosed
US-20240376044-A1 METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2024-11-14 US disclosed
US-20240342186-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2024-10-17 US disclosed
US-12071396-B2 Method for preparing aromatic amino acid derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-08-27 US disclosed
US-20240245699-A1 PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SERVIER LAB (FR) 2024-07-25 US disclosed
WO-2008057469-A1 SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION WYETH (US) 2008-05-15 WO disclosed
US-20080058521-A1 Processes for the preparation of compounds WYETH (US) 2008-03-06 US disclosed
US-20080058521-A1 Processes for the preparation of compounds WYETH (US) 2008-03-06 US disclosed
US-20080058521-A1 Processes for the preparation of compounds WYETH (US) 2008-03-06 US disclosed
WO-2007089669-A2 PROCESSES FOR THE PREPARATION OF COMPOUNDS WHICH MODULATE CELL PROLIFERATION WYETH (US) 2007-08-09 WO disclosed
WO-2007089669-A2 PROCESSES FOR THE PREPARATION OF COMPOUNDS WHICH MODULATE CELL PROLIFERATION WYETH (US) 2007-08-09 WO disclosed
EP-1270582-B1 TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES MITSUBISHI RAYON CO (JP) 2006-08-30 EP disclosed
US-6693210-B2 USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS MITSUBISHI RAYON CO., LTD. (JP) 2004-02-17 US disclosed
US-20030065208-A1 Using palladium, nickel phosphine complex as catalysts MITSUBISHI RAYON CO., LTD. (JP) 2003-04-03 US disclosed
EP-1270582-A1 TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE Mitsubishi Rayon Co., Ltd. (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058521-A1 Processes for the preparation of compounds MKI67, MCL1, DCX ALDH1A1 1315/4885KDM4E 1883/4885SMN1; SMN2 1131/4885
US-20240376044-A1 METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE DDC, AADAT, TYR ALDH1A1 1120/4885KDM4E 626/4885SMN1; SMN2 4796/4885
US-20030065208-A1 Using palladium, nickel phosphine complex as catalysts PDCD1LG2, PIK3CA, PDCD1 ALDH1A1 3993/4885KDM4E 2983/4885SMN1; SMN2 4601/4885
US-20240245699-A1 PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PDCD11, RRM2B, RRM2 ALDH1A1 1180/4885KDM4E 1783/4885SMN1; SMN2 2908/4885
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR ALDH1A1 3927/4885KDM4E 4591/4885SMN1; SMN2 3096/4885
US-20240342186-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS CGAS, GLS2, GMPS ALDH1A1 1112/4885KDM4E 3126/4885SMN1; SMN2 2556/4885
US-12202816-B2 Compounds as NADPH oxidase inhibitors CYBB, NOX1, NOX4 ALDH1A1 285/4885KDM4E 3830/4885SMN1; SMN2 1707/4885
US-20250360141-A1 PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS CGAS, GLS2, GMPS ALDH1A1 1206/4885KDM4E 3243/4885SMN1; SMN2 2437/4885
US-12433897-B2 Pyridine derivatives with n-linked cyclic substituents as cGAS inhibitors CGAS, GLS2, GMPS ALDH1A1 1112/4885KDM4E 3126/4885SMN1; SMN2 2556/4885
US-12071396-B2 Method for preparing aromatic amino acid derivative DDC, AADAT, TYR ALDH1A1 1120/4885KDM4E 626/4885SMN1; SMN2 4796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.